Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 7, 2014, Pages 804-810

  Patwardhan, V R ^a   Sengupta, N ^a   Bonder, A ^a   Lau, D ^a   Afdhal, N H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; GUANINE; NUCLEOSIDE; NUCLEOTIDE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RELAPSE; RETREATMENT; TREATMENT DURATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; HEPATITIS B, CHRONIC; MIDDLE AGED; RECURRENT DISEASE; TREATMENT WITHDRAWAL; YOUNG ADULT;

ADENINE; ADULT; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; ORGANOPHOSPHONATES; RECURRENCE; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84908117186     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12908     Document Type: Article

References (40)

1. Hadziyannis S. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
2. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
3. Brunetto MR, Giarin M, Oliveri F, et al. "e" antigen defective hepatitis B virus and course of chronic infection. J Hepatol 1991; 13(Suppl. 4): S82-6.
4. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-70.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 1: 57.
6. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008 Dec 4; 359: 2442-55.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
8. Lai C-L, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
9. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
10. Ha M, Zhang G, Diao S, et al. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol 2012; 157: 285-90.
11. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-6.
12. Huang Y-H, Wu JC, Chang T-T, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003; 10: 277-84.
13. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-8.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
15. Chan HL-Y, Wang H, Niu J, Chim AM-L, Sung JJY. Two-year lamivudine treatment for hepatitis B e antigennegative chronic hepatitis B: a doubleblind, placebo-controlled trial. Antivir Ther (Lond) 2007; 12: 345-53.
16. Shouval D, Lai C-L, Chang T-T, et al. Relapse of hepatitis B in HBeAgnegative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50: 289-95.
17. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.
18. Liu F, Wang L, Li XY, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011; 26: 456-60.
19. Seto W-K, Hui AJ, Wong VW-S, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2014; doi:10.1136/gutjnl-2014-307237.
20. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
21. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
22. Kim SU, Park JY, Kim DY, et al. Noninvasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int 2010; 4: 673-80.
23. Jang W, Yu SI, Sinn DH, et al. Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos (t)ide analogue. Clin Res Hepatol Gastroenterol 2014; 38: 195-200.
24. Ma J-J, Ding H, Mao F, Sun H-C, Xu C, Wang W-P. Assessment of liver fibrosis with elastography point quantification technique in chronic hepatitis B virus patients: a comparison with liver pathological results. J Gastroenterol Hepatol 2014; 29: 814-9.
25. Chang T-T, Liaw Y-F, Wu S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
26. Toy M. Cost-effectiveness of viral hepatitis B & C treatment. Best Pract Res Clin Gastroenterol 2013; 27: 973-85.
27. Du X, Wang J, Shao L, et al. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. J Viral Hepat 2013; 20: 328-35.
28. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
29. Reijnders JGP, Janssen HLA. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty? Hepatology 2013; 58: 1885-7.
30. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Loss of HBsAg in HBeAg neg pts Gastro 2012. Gastroenterology 2012; 143:629-36. e1.
31. Wong GLH, Wong VW-S, Chan H-Y, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther 2012; 35: 1326-35.
32. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
33. Wang H, Xue L, Yan R, et al. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS ONE 2013; 8: e80585.
34. Jeng W-J, Sheen I-S, Chen Y-C, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58: 1888-96.
35. Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014; 39: 629-37.
36. Sheen E, Trinh HN, Nguyen TT, et al. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. Aliment Pharmacol Ther 2011; 34: 767-74.
37. Gordon SC, Lamerato LE, Rupp LB, et al. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population. Clin Gastroenterol Hepatol 2014; 12: 885-93.
38. Lim Y-S, Han S, Heo N-Y, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014; 147: 152-61.
39. Singal AK, Salameh H, Kuo Y-F, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106.
40. Sung JJY, Tsoi KKF, Wong VW-S, Li KCT, Chan HL-Y. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.